Plasma Exchange for Hantavirus Pulmonary Syndrome: A Mechanistic Case for an Untested Intervention
B1 Crossref Works API · 2026-09-28 · United States · ANDV
ABSTRACT Hantavirus pulmonary syndrome (HPS) carries a case fatality rate of 35%–40% and has no approved pharmacologic treatment. Its pathophysiology is rooted in the plasma compartment: cytokines, viral antigens, immune complexes, and platelet‐binding glycoproteins circulate as drivers of immunopathologic endothelial injury, noncardiogenic pulmonary edema, and cardiogenic depression. Therapeutic plasma exchange (TPE) achieves bulk clearance of plasma‐borne mediators and is established by the American Society for Apheresis (ASFA) for numerous indications that share an analogo
Read at source (Crossref Works API) →
HORIZON metadata
| Source | Crossref Works API (crossref) |
|---|---|
| NATO rating | B1 — see methodology |
| Country | United States |
| Serotype | ANDV |
| Reported date | 2026-09-28 |
| Ingested at | 2026-09-29 12:50 UTC |